What the Top 10 Biopharma CEOs Are Making
Surging Markets Drive Double- and Triple-Digit Percentage Gains for Compensation
Exosomes from Cancer Cells Could Predict Immunotherapy Responses
Immune-Evasion Mechanism May Help Explain the Differences in Responses to Immunotherapy
Bioreactors Pull Out Some of the Stops
Balancing Bioreactor and Process Parameters Avoids Production Discord and Amplifies Flows
Improving CRISPR-Cas9’s Rate of Homology-Directed Repair
Integrated DNA Technologies Suggests Strategies to Boost Efficiency, Avoid Blunt-End Incorporation, and Reduce Toxicity
Lynne Lederman Ph.D.
Lynne Lederman, Ph.D.